Edison Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to EPI-743, the company’s lead drug, for the treatment of Friedreich’s ataxia. EPI-743 is being developed for pediatric and adult mitochondrial disease, including Friedreich’s ataxia. 

 

EPI-743 has successfully completed Phase 1 and multiple Phase 2 studies. In these studies, EPI-743 has been demonstrated to be safe and well tolerated. Two Phase 2 trials in patients with Friedreich’s ataxia are ongoing. A Phase 2B randomized double-blind placebo-controlled trial in adults with Friedreich’s ataxia is fully enrolled. It is expected to be completed in Q3, 2014. In addition, EPI-743 is being evaluated in a rare Friedreich’s ataxia genetic subtype- patients with a point mutation in the gene encoding frataxin. This single-arm subject-controlled trial is also fully enrolled. Details of these trials can be found on clinicaltrials.gov. 

 

“Fast Track designation will facilitate Edison’s clinical development of EPI-743 for patients with Friedreich’s ataxia,” said Guy Miller, chairman and CEO of Edison Pharmaceuticals. “We are fully committed to delivering the first approved drug for this highly debilitating and lethal disease for which there are no FDA-approved therapies.”

 

The FDA’s Fast Track program is designed to facilitate the development of drugs that have demonstrated potential to treat diseases that are serious, life threatening, and for which there is an unmet medical need. Fast Track provides a number of benefits, including the ability to meet and communicate more frequently with the FDA to discuss drug development plans, as well as eligibility for accelerated approval. Drugs with Fast Track designation may also receive “rolling review” from the FDA. This permits a drug company to submit completed portions of a New Drug Application (NDA) for immediate review before the entire application is completed. 

 

“We greet with tremendous enthusiasm the FDA’s issuance of Fast Track designation to EPI-743 for Edison’s Friedreich’s ataxia development program,” said Ron Bartek, president, Friedreich’s Ataxia Research Alliance (FARA) and chairman of the board of the National Organization for Rare Disorders. “This demonstrates the FDA’s commitment to the accelerated development of promising drugs for diseases which have no treatments.”

 

The FDA has previously granted Orphan designation status to EPI-743 for the treatment of Friedreich’s ataxia.

 

Date: March 17, 2014

Source: Edison Pharmaceuticals